- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03441841
Pharmacokinetic Study of Nanoencapsulated Gel of Lidocaine, Prilocaine and Combination of Lidocaine and Prilocaine
A Cross-over Study of Pharmacokinetic Interaction Comparing Nanoencapsulated Gel of Prilocaine (2.5%), Lidocaine (2.5%) and Association of Prilocaine + Lidocaine 2.5% (Nanorap®) Topically in Healthy Volunteers.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was performed as a monocentric, open, randomized, double-blind, with 3 treatment regimen (lidocaine, prilocaine, or Nanorap®) in 3 periods design. Volunteers were submitted to clinical and laboratory examination before enrollment. Treatments were carried out on 3 different days with a washout period of 7 days between each dose.
After a fasting period (8 h), volunteers received topically 2g of the formulation in a delimited area of 16 cm2 in the volar surface of the forearm. The product was applied to the left arm and venous blood was collected from the right arm. The remaining product was removed with a cotton swab 10 minutes after application. Blood samples (3.5 mL) were collected into heparinized tubes before (0:00) and at 1.0, 2.0, 3.0, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 12.0, 14.0, 16.0 and 24.0 h after the hydrogel application.
Blood samples were centrifuged at 2000 g (4 ⁰C) for 10 minutes and the obtained plasma samples were stored at -20 °C until analysis.
Following dosing, volunteers were monitored for 36 h in a clinical setting safety and tolerability (signs, symptoms, adverse events, and laboratory parameters). The vital signs (blood pressure and pulse rate) were evaluated. ECGs were obtained before (30 min) and at drug Cmax (6 h) for each product application. QT interval corrected by heart rate (QTc) data were obtained from a Bionet Cardiocare 2000 and BMS-Plus software program, using Bazett's formula: QTc = QT/(sqrt RR Interval).
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
SP
-
Campinas, SP, Brazil
- Galeno Desenvolvimento de Pesquisas Clinicas Ltda. - ME
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers over 18 years old
- Body mass index (BMI) ≥ 19.0 kg/m² and ≤ 28.75 kg/m²
- No evidence of significant diseases, that, at the investigator's discretion, may affect the participation in the clinical trial, in accordance with the protocol requirements
- Ability to understand the nature and the objective of the clinical trial,including the risks and possible side effects; intention to cooperate with the investigator and act in accordance with the protocol requirements, as confirmed by the informed consent form signature.
Exclusion Criteria:
- Subjects with known hypersensitivity to the compounds of the investigational products, severe allergies or multiple drug allergies
- Existing diseases or pathological findings, which might interfere with the safety or tolerability, and/or pharmacokinetics of the drug
- Screening laboratory tests presenting deviations deemed as clinically significant, which, due to possible risks, prevents the participation in clinical trial.
- Use of maintenance therapy with any drug
- Drug or alcohol dependence
- Volunteers who ingests more than 5 cups of coffee or tea per day and/or smoke
- Volunteers with unusual eating habits, e.g, vegetarian
- Treatment, within 3 months prior to the initiation of the clinical trial treatment, with any drug known to have a well-established toxic potential to major organs.
- Use of regular medication within 2 weeks before the start of treatment and the date of evaluation, or made use of any medication within one week, except for oral contraceptives or cases where, based on the half-life of the drug and/or active metabolites, complete elimination can be assumed
- Treatment within 6 months prior to the study with any known drug of have a well-defined toxic potential in large organs
- Hospitalization for any reason up to 8 weeks before the start of the treatment of this study
- Participation in a clinical trial during the last 6 months
- Blood donation or other blood loss of more than 450 mL within the last 3 months
- Pregnant, delivery or abortion in the 12 weeks prior to the planned hospitalization
- The volunteer who has any condition that prevents him from participating in the study by judgment of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Lidocaine + prilocaine
Single topical dose of a combination of nanoencapsulated lidocaine (2.5%) and prilocaine (2.5%) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
|
Single topical dose of 2g lidocaine + prilocaine 2.5 % formulation.
Other Names:
|
Active Comparator: Lidocaine
Single topical dose of lidocaine nanoencapsulated gel (2.5 %) formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
|
Single topical dose of 2g lidocaine 2.5 % formulation.
|
Active Comparator: Prilocaine
Single topical dose of prilocaine (2.5 %) nanoencapsulated gel formulation in a delimited area of 16 cm2 in the volar surface of the forearm.
|
Single topical dose of 2g prilocaine 2.5 % formulation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of lidocaine and prilocaine plasma levels
Time Frame: 0-24 h
|
Blood sampling for the determination of plasma levels of lidocaine and prilocaine in participants of each treatment group.
|
0-24 h
|
Maximum Plasma Concentration (Cmax) of lidocaine and prilocaine
Time Frame: 0-24 h
|
Determination of Cmax for lidocaine and prilocaine based on plasma concentrations of samples obtained.
|
0-24 h
|
Area Under the Curve (AUC) of lidocaine and prilocaine
Time Frame: 0-24 h
|
Determination of AUC for lidocaine and prilocaine based on plasma concentrations of samples obtained.
|
0-24 h
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of adverse events per participant
Time Frame: Up to 36 h after treatment
|
Determination of the number of adverse events, in each treatment group, including clinically relevant alterations of vital signs and laboratory tests results.
|
Up to 36 h after treatment
|
Collaborators and Investigators
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Sensory System Agents
- Anesthetics
- Membrane Transport Modulators
- Anesthetics, Local
- Voltage-Gated Sodium Channel Blockers
- Sodium Channel Blockers
- Anesthetics, Combined
- Lidocaine
- Prilocaine
- Lidocaine, Prilocaine Drug Combination
Other Study ID Numbers
- GDN 002/16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Topical Anesthesia
-
Bassett HealthcareCompleted
-
Indonesia UniversityCompletedAdult Patients Undergoing Phacoemulsification With Topical AnesthesiaIndonesia
-
Mayo ClinicRecruitingAnesthesia, Local | Photodamaged Skin | Topical and Infiltration Anesthetic ToxicityUnited States
-
Milton S. Hershey Medical CenterCompleted
-
University of Campinas, BrazilFundação de Amparo à Pesquisa do Estado de São PauloCompletedAdministration, Topical | Administration, Topical Drug | Anesthetic DrugsBrazil
-
Innoture LtdCompletedTopical AnaesthesiaUnited Kingdom
-
University of BernCompletedDental Trauma | Avulsion | Periodontal Regeneration | Pulpal Regeneration | Topical Dexamethasone | Topical TetracyclineSwitzerland
-
Loma Linda UniversityInnovadonticsCompletedTopical Anesthetic Applied With SonophoresisUnited States
-
University Hospitals Coventry and Warwickshire...University Hospital, GenevaTerminatedTopical Corticosteroid-treated Dermatology Patients | Intra-ocular PressureUnited Kingdom
Clinical Trials on Lidocaine + Prilocaine
-
Ohio State University Comprehensive Cancer CenterRecruitingMerkel Cell Carcinoma | Cutaneous Melanoma | Skin Squamous Cell CarcinomaUnited States
-
Poitiers University HospitalCompleted
-
Assiut UniversityCompleted
-
IRCCS Burlo GarofoloCompletedProcedural Pain ReliefItaly
-
Cairo UniversityNot yet recruiting
-
Montefiore Medical CenterCompletedPain | Needle PhobiaUnited States
-
Plethora Solutions LtdShionogi Inc.CompletedPremature EjaculationUnited States
-
Assistance Publique - Hôpitaux de ParisUnknown
-
Galeno Desenvolvimento de Pesquisas ClínicasBiolab Sanus FarmaceuticaCompletedLidocaine Adverse Reaction | Prilocaine Adverse ReactionBrazil